Potential Immune Microenvironment Biomarkers in SCLC: J-TAIL-2 Observational Study - PubMed
4 hours ago
- #Biomarkers
- #Immunotherapy
- #SCLC
- The study explores potential immune microenvironment biomarkers in extensive-stage small cell lung cancer (ES-SCLC) treated with atezolizumab plus carboplatin/etoposide (CE).
- CD8+ tumor-infiltrating lymphocyte (TIL) density was identified as a potential biomarker, with higher density associated with better progression-free survival (PFS) and overall survival (OS).
- SCLC subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-O) were evaluated, but no significant survival differences were found among them, though SCLC-N showed numerically shorter survival.
- The study suggests CD8+ TIL density could help in selecting patients for atezolizumab combination therapy in ES-SCLC.
- The research was conducted as part of the J-TAIL-2 observational study in Japan, involving 100 SCLC patients.